Clinical Trials Browser

Phase 2 × Hematologic Diseases × idecabtagene vicleucel × Clear all

NCT05032820 2026-03-05

Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma

Phase 2 Completed

40 enrolled 21 charts

Hematologic Diseases, Multiple Myeloma